首页|期刊导航|中国临床药理学杂志|低蛋白血症和显著低蛋白血症对万古霉素血药谷浓度影响的临床研究

低蛋白血症和显著低蛋白血症对万古霉素血药谷浓度影响的临床研究OA

Clinical trial of the effects of hypoalbuminemia and significant hypoalbuminemia on vancomycin trough concentrations

中文摘要英文摘要

目的 研究低蛋白血症和显著低蛋白血症对万古霉素血药谷浓度的影响.方法 将在本院检查万古霉素血药浓度的患者,根据患者的血浆白蛋白(ALB)进行2种分组:一种为低蛋白血症组(ALB<35 g·L-1)和非低蛋白血症组(ALB≥35 g·L-1);另一种为显著低蛋白血症组(ALB<30 g·L-1)和非显著低蛋白血症组(ALB≥30 g·L-1).对患者的性别、年龄、体表面积、身体质量指数(BMI)、实验室检查指标、头孢唑林、头孢曲松等联合用药情况进行倾向性评分匹配(PSM),比较低蛋白血症组和非低蛋白血症组的万古霉素血药谷浓度、微生物结局和治疗结局差异,以及显著低蛋白血症组和非显著低蛋白血症组的万古霉素血药谷浓度、微生物结局和治疗结局差异.结果 本研究最终纳入患者584例.低蛋白血症组和非低蛋白血症组PSM后,每组各69例患者,万古霉素血药谷浓度分别为 14.10(7.25,18.84)和 12.10(8.15,17.75)μg·mL-1,微生物清除率分别为79.70%(59例/69例)和84.10%(58例/69例),治疗有效率分别为82.60%(57例/69例)和84.10%(58例/69例),在统计学上差异均无统计学意义(均P>0.05);显著低蛋白血症组和非显著低蛋白血症组PSM后,每组各82例患者,万古霉素血药谷浓度分别为17.15(12.23,21.55)和14.40(9.38,19.20)μg·mL-1,在统计学上差异有统计学意义(P<0.05);微生物清除率分别为93.90%(77例/82例)和87.80%(72例/82例),临床治疗有效率分别为91.50%(75例/82例)和87.80%(72例/82例),在统计学上差异均无统计学意义(均P>0.05).结论 低蛋白血症对万古霉素的影响相对较小,但显著低蛋白血症可能增加万古霉素血药浓度,需注意监测血药浓度.

Objective To investigate the effect of hypoproteinemia and significant hypoalbuminemia on vancomycin trough concentration.Methods Patients who had vancomycin trough concentration checked in our hospital were categorized into two classification systems based on albumin(ALB):one dividing patients into hypoalbuminemia group(ALB<35 g·L-1)and non-hypoalbuminemia group(ALB≥35 g·L-1);and the other into significant hypoalbuminemia group(ALB<30 g·L-1)and non-significant hypoalbuminemia group(ALB≥30 g·L-1).Propensity score matching(PSM)was conducted for the patients' gender,age,body surface area,body mass index(BMI),laboratory test indicators,comorbidities,and concomitant medications such as cefazolin and ceftriaxone,to make the baseline conditions of the patients comparable.Differences in vancomycin trough concentrations,microbiological outcomes,and therapeutic outcomes were compared between the hypoalbuminemia and non-hypoalbuminemia groups,as well as between the significant and non-significant hypoalbuminemia groups.Results This study included 584 patients.After matching hypoalbuminemia group with non-hypoalbuminemia group,there were 69 patients in each group.The vancomycin trough concentrations were 14.10(7.25,18.84)and 12.10(8.15,17.75)μg·mL-1,respectively;microbiological clearance rates were 79.70%(59 cases/69 cases)and 84.10%(58 cases/69 cases),respectively;and clinical effective rates were 82.60%(57 cases/69 cases)and 84.10%(58 cases/69 cases),respectively;compared between 2 groups,the differences of the above indicators were not statistically significant(all P>0.05).Additionally,after matching significant hypoalbuminemia group with non-significant hypoalbuminemia group,there were 82 patients in each group.The vancomycin trough concentrations were 17.15(12.23,21.55)and 14.40(9.38,19.20)μg·mL-1,and the difference was statistically significant(P<0.05).The microbial eradication rates were 93.90%(77 cases/82 cases)and 87.80%(72 cases/82 cases),respectively;and clinical effective rates were 91.50%(75 cases/82 cases)and 87.80%(72 cases/82 cases),respectively;but no statistically signifcant differences were found in microbial eradication rates and clinical effective rates(all P>0.05).Conclusion Hypoproteinemia has a relatively minor impact on vancomycin trough concentration,however,significant hypoproteinemia may increase vancomycin trough concentration.In clinical practice,it is necessary to monitor vancomycin trough concentration in patients with significant hypoproteinemia.

陈清;吴权煌;张敏新;黄爱文

中国人民解放军联勤保障部队第九○○医院临床药学科,福建 福州 350025福建中医药大学药学院,福建 福州 350122中国人民解放军联勤保障部队第九○○医院临床药学科,福建 福州 350025中国人民解放军联勤保障部队第九○○医院临床药学科,福建 福州 350025

医药卫生

万古霉素低蛋白血症显著低蛋白血症血药浓度

vancomycinhypoproteinemiasignificant hypoalbuminemiatrough concentration

《中国临床药理学杂志》 2026 (12)

1679-1685,7

福建省青年科技人员育成基金资助项目(2025350844)

10.13699/j.cnki.1001-6821.2026.12.005

评论